Characteristics of patients with hepatitis C virus with and without GB virus C/Hepatitis G virus Co‐infection and efficacy of interferon alfa
M. Enomoto, S. Nishiguchi, K. Fukuda
May 1, 1998
Citations
26
Citations
Quality indicators
Journal
Hepatology
Full text
Semantic Scholar
Key Takeaway Key Takeaway: Interferon alfa treatment is sometimes effective against GBV-C/HGV, and anti-E2 may be associated with clearance of GBV-C/HGV, but GBV-C/HGV infection does not affect the severity of HCV-related disease.
Abstract
GB virus C/hepatitis G virus (GBV‐C/HGV) infection seems to be common among patients with hepatitis C virus (HCV) infection. We studied retrospectively the proportions of patients with GBV‐C/HGV RNA and antibodies to the GBV‐C/HGV second envelope protein (anti‐E2) among 149 subjects with chronic hepatitis C who had received interferon alfa. The clinical characteristics of patients with GBV‐C/HGV RNA or anti‐E2 were examined, as was the efficacy of the treatment. Stored serum specimens were tested for GBV‐C/HGV RNA by the reverse transcription polymerase chain reaction and for anti‐E2 by an enzyme‐linked immunosorbent assay. Of the 149 patients before therapy, 8 (5%) had GBV‐C/HGV RNA only, 72 (48%) had anti‐E2 only, and 4 (3%) had both. The mean age of patients with GBV‐C/HGV RNA (some with anti‐E2) was significantly less than that of patients with anti‐E2 only. Results of laboratory and histological evaluations were not different depending on the presence of GBV‐C/HGV RNA or anti‐E2. The GBV‐C/HGV RNA titer decreased during therapy in all 12 patients with GBV‐C/HGV RNA; only 4, with a low titer before therapy and with anti‐E2 detected at some time, had sustained clearance of GBV‐C/HGV. Our results suggested that half of the patients with chronic hepatitis C had been exposed to GBV‐C/HGV, but in almost all, the virus had been cleared; also, even chronic GBV‐C/HGV infection did not affect the severity of the disease arising from HCV. Interferon alfa treatment was sometimes effective against GBV‐C/HGV, and anti‐E2 may be associated with clearance of GBV‐C/HGV.